MedTrace Logo

Efficacy of Oral Vitamin D Supplementation in Adolescents and Young Adults.

NCT04377386 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2024-02-01

No results posted yet for this study

Summary

This study assesses whether oral supplementation with vitamin D contributes to the reduction of body mass index and lipid profile in adolescents and young adults. The intervention group will receive 1000 IU of vitamin D (DV) and the control group 200 IU of DV.

Conditions

  • Overweight and Obesity
  • Overweight Adolescents
  • Vitamin D Deficiency

Interventions

DIETARY_SUPPLEMENT

1000 IU D vitamin

Participants in the intervention group will receive 105 DV doses of 1000 IU. The supplementation will be given by the Farma de Colombia laboratory, known commercially as Farma D, whose presentation is in soft gelatin capsules. It is recommended to take one dose per day at the same time and participants should record the daily intake time of the supplement for 15 weeks on a calendar.

DIETARY_SUPPLEMENT

200 IU D vitamin

Participants in the control group will receive 105 DV doses of 200 IU. The supplementation will be given by the same laboratory; it will have the same characteristics and recommendations for the intake as for the intervention group.

Sponsors & Collaborators

  • Universidad Industrial de Santander

    collaborator OTHER

  • Farma de Colombia SA

    collaborator INDUSTRY

  • Fundación Cardiovascular de Colombia

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-08-03
Primary Completion
2020-11-02
Completion
2021-02-02

Countries

  • Colombia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04377386 on ClinicalTrials.gov